Stock comparison
Catalyst Pharmaceuticals
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CPRX
Catalyst Pharmaceuticals
Market cap
$3.83B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CPRX | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 69C | 72B | LLY |
| Benjamin Graham | 75B | 86A | LLY |
| Philip Fisher | 87C | 86A | CPRX |
| Peter Lynch | 65B | 74B | LLY |
| Joel Greenblatt | 42D | 78C | LLY |
| Charlie Munger | 78B | 85A | LLY |
| Terry Smith | 78B | 77C | CPRX |
Side-by-side metrics
| Metric | CPRX | LLY |
|---|---|---|
| Market cap | $3.83B | $1T |
| P/E (TTM) | 17.3x | 36.6x |
| EV/EBIT | 11.9x | 34.1x |
| ROIC (TTM) | 19.67% | 32.06% |
| Gross margin | 82.32% | 83.51% |
| Net margin | 37.08% | 34.98% |
| Revenue CAGR 5y | 43.0% | 23.17% |
| EPS CAGR 5y | 46.49% | 40.81% |
| Debt / Equity | 0.0x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CPRX leads on
- Debt / Equity0.0xvs 1.4x+100%
- EV/EBIT11.9xvs 34.1x+65%
- P/E (TTM)17.3xvs 36.6x+53%
- Revenue CAGR 5y43.0%vs 23.17%+46%
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $3.83B+100%
- ROIC (TTM)32.06%vs 19.67%+39%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.